GlassScriptPhysician profile
Katherine A Macoul
NPI 1710071691
$1,476.21
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $161 · 2021: $492 · 2022: $360.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $238.41 | 2021 | |
| Allergan, INC. | $229.03 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $164.77 | 2021-2022 | |
| New World Medical,INC. | $155.74 | 2021 | |
| Aerie Pharmaceuticals, INC. | $135.93 | 2019-2020 | |
| Horizon Therapeutics Plc | $124.99 | 2020 | |
| Abbvie INC. | $123.26 | 2022 | |
| Ivantis, INC | $116.62 | 2019 | |
| Mallinckrodt Enterprises LLC | $66.34 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $38.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.53 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.60 | 2022 | |
| Oyster Point Pharma, INC. | $22.22 | 2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Macoul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.